Moscow, Russia - 10 April 2015 - Novo Nordisk has opened a new manufacturing facility in Russia for formulation and filling of modern insulin for the treatment of diabetes. The production will cover both Penfill®cartridges and FlexPen® prefilled insulin injection pens for the Russian market.
Located in Technopark Grabtsevo in the Kaluga region of Russia, this is the first and only greenfield facility for the manufacturing of modern insulin in Russia. With the construction of the new facility, Novo Nordisk has so far created around 150 new jobs.
"The manufacturing facility in Kaluga is a sign of our long-term commitment to people with diabetes in Russia, where close to 10 million people have the disease according to local studies. With our investment in local manufacturing, we ensure availability of high-quality modern insulins to the people with diabetes in Russia who rely on our products every day," said Lars Rebien Sørensen, CEO of Novo Nordisk.
Novo Nordisk also has production sites in Denmark, Brazil, China, France and the US.